Enhanced bone regeneration via endochondral ossification using Exendin-4-modified mesenchymal stem cells
Source abstract
Abstract
Nonunions and delayed unions pose significant challenges in orthopedic treatment, with current therapies often proving inadequate. Bone tissue engineering (BTE), particularly through endochondral ossification (ECO), emerges as a promising strategy for addressing critical bone defects. This study introduces mesenchymal stem cells overexpressing Exendin-4 (MSC-E4), designed to modulate bone remodeling via their autocrine and paracrine functions. We established a type I collagen (Col-I) sponge-based in vitro model that effectively recapitulates the ECO pathway. MSC-E4 demonstrated superior chondrogenic and hypertrophic differentiation and enhanced the ECO cell fate in single-cell sequencing analysis. Furthermore, MSC-E4 encapsulated in microscaffold, effectively facilitated bone regeneration in a rat calvarial defect model, underscoring its potential as a therapeutic agent for bone regeneration. Our findings advocate for MSC-E4 within a BTE framework as a novel and potent approach for treating significant bone defects, leveraging the intrinsic ECO process.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Connective tissue disorders research · Mesenchymal stem cell research · Heterotopic Ossification and Related Conditions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (75)
Show source-provided references
1. Ismailidis, P., et al., Scope and limits of teriparatide use in delayed and nonunions: a case series. Clin. Practice. 11(1): p. 47-57..10.3390/clinpract11010009 ↗
2. Hak, D.J., et al., Delayed union and nonunions: epidemiology, clinical issues, and financ ial aspects. Injury. 45 Suppl 2: p. S3-S7..10.1016/j.injury.2014.04.002 ↗
3. Lerner, R.K., et al., Quality of life assessment of patients with posttraumatic fracture non union, chronic refractory osteomyelitis, and lower-extremity amputatio n. Clin. Orthop. Relat. Res., (295): p. 28-36..10.1097/00003086-199310000-00006 ↗
4. Trejo-Iriarte, C.G., et al., Evaluation of bone regeneration in a critical size cortical bone defec t in rat mandible using microCT and histological analysis. Arch. Oral Biol.. 101: p. 165-171..10.1016/j.archoralbio.2019.01.010 ↗
5. Nicholson, J.A., et al., Fracture nonunion in long bones: a literature review of risk factors a nd surgical management. Injury. 52 Suppl 2: p. S3-S11..10.1016/j.injury.2020.11.029 ↗
6. Qi, J., et al., Current biomaterial-based bone tissue engineering and translational me dicine. Int. J. Mol. Sci.. 22(19): p. 10233..10.3390/ijms221910233 ↗
7. Ho-Shui-Ling, A., et al., Bone regeneration strategies: engineered scaffolds, bioactive molecule s and stem cells current stage and future perspectives. Biomaterials. 180: p. 143-162..10.1016/j.biomaterials.2018.07.017 ↗
8. Koons, G.L., M. Diba, and A.G. Mikos, Materials design for bone-tissue engineering. Nat. Rev. Mater.. 5(8): p. 584-603..10.1038/s41578-020-0204-2 ↗
9. Fu, J., et al., Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis. Stem Cell Res. Ther., 2021. 12(1): p. 377..10.1186/s13287-021-02456-w ↗
10. Bunpetch, V., et al., Strategies for MSC expansion and MSC-based microtissue for bone regene ration. Biomaterials. 196: p. 67-79..10.1016/j.biomaterials.2017.11.023 ↗
11. Freitas, J., et al., Genetically engineered-MSC therapies for non-unions, delayed unions an d critical-size bone defects. Int. J. Mol. Sci.. 20(14): p. 3430..10.3390/ijms20143430 ↗
12. Zhou, T., et al., Challenges and advances in clinical applications of mesenchymal stroma l cells. J. Hematol. Oncol.. 14(1): p. 24..10.1186/s13045-021-01037-x ↗
13. Moysidou, C.-M., C. Barberio, and R.M. Owens, Advances in engineering human tissue models. Front. Bioeng. Biotechnol.. 8: p. 620962..10.3389/fbioe.2020.620962 ↗
14. Xing, D., et al., Engineering 3D functional tissue constructs using self-assembling cell -laden microniches. Acta Biomater.. 114: p. 170-182..10.1016/j.actbio.2020.07.058 ↗
15. Li, H., et al., Self-assembled microtissues loaded with osteogenic MSCs for in vivo bone regeneration. Front. Bioeng. Biotechnol.. 10: p. 1069804..10.3389/fbioe.2022.1069804 ↗
16. Wang, B., et al., A low dose cell therapy system for treating osteoarthritis: in vivo study and in vitro mechanistic investigations. Bioact. Mater.. 7: p. 478-490..10.1016/j.bioactmat.2021.05.029 ↗
17. Salhotra, A., et al., Mechanisms of bone development and repair. Nat. Rev. Mol. Cell Biol.. 21(11): p. 696-711..10.1038/s41580-020-00279-w ↗
18. Stegen, S., et al., HIF-1α metabolically controls collagen synthesis and modification in c hondrocytes. Nature. 565(7740): p. 511-515..10.1038/s41586-019-0874-3 ↗
19. Fu, R., et al., Bone defect reconstruction via endochondral ossification: a developmen tal engineering strategy. J. Tissue Eng.. 12: p. 20417314211004211..10.1177/20417314211004211 ↗
20. Bernhard, J., et al., Tissue-engineered hypertrophic chondrocyte grafts enhanced long bone r epair. Biomaterials. 139: p. 202-212..10.1016/j.biomaterials.2017.05.045 ↗
21. Zhang, X., et al., Msx1+ stem cells recruited by bioactive tissue engineering graft for bone regeneration. Nat. Commun.. 13(1): p. 5211..10.1038/s41467-022-32868-y ↗
22. Zhang, M., et al., Recapitulation of cartilage/bone formation using iPSCs via biomimetic 3D rotary culture approach for developmental engineering. Biomaterials. 260: p. 120334..10.1016/j.biomaterials.2020.120334 ↗
23. Helsted, M.M., et al., The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone. 140: p. 115553..10.1016/j.bone.2020.115553 ↗
24. Yamada, C., et al., The murine glucagon-like peptide-1 receptor is essential for control o f bone resorption. Endocrinology. 149(2): p. 574-579..10.1210/en.2007-1292 ↗
25. Mabilleau, G., et al., Optimal bone mechanical and material properties require a functional g lucagon-like peptide-1 receptor. J. Endocrinol.. 219(1): p. 59-68..10.1530/JOE-13-0146 ↗
26. Nuche-Berenguer, B., et al., Presence of a functional receptor for GLP-1 in osteoblastic cells, ind ependent of the cAMP-linked GLP-1 receptor. J. Cell. Physiol.. 225(2): p. 585-592..10.1002/jcp.22243 ↗
27. Kim, J.-Y., et al., Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocy tes. Life Sci.. 92(10): p. 533-540..10.1016/j.lfs.2013.01.001 ↗
28. Nuche-Berenguer, B., et al., Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif. Tissue Int., 2009. 84(6): p. 453-461..10.1007/s00223-009-9220-3 ↗
29. Nuche-Berenguer, B., et al., GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J. Endocrinol.. 209(2): p. 203-210..10.1530/JOE-11-0015 ↗
30. Ma, X., et al., Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteop enia by promoting bone formation and suppressing bone resorption in ag ed ovariectomized rats. J. Bone Miner. Res. : Off. J. Am. Soc. Bone Mineral Res.. 28(7): p. 1641-1652..10.1002/jbmr.1898 ↗
31. Sun, H.-X., et al., The bone-preserving effects of exendin-4 in ovariectomized rats. Endocrine. 51(2): p. 323-332..10.1007/s12020-015-0667-x ↗
32. Liraglutide promotes osteoblastic differentiation in mc3t3-E1 cells by ERK5 pathway10.1155/2020/8821077 ↗
33. Pal, S., et al., The osteogenic effect of liraglutide involves enhanced mitochondrial b iogenesis in osteoblasts. Biochem. Pharmacol.. 164: p. 34-44..10.1016/j.bcp.2019.03.024 ↗
34. Zhai, S., et al., Glucagon-like peptide-1 receptor promotes osteoblast differentiation o f dental pulp stem cells and bone formation in a zebrafish scale regen eration model. Peptides. 163: p. 170974..10.1016/j.peptides.2023.170974 ↗
35. Wu, X., et al., Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates o steogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signa ling pathways involving β-catenin. Exp. Cell Res.. 360(2): p. 281-291..10.1016/j.yexcr.2017.09.018 ↗
36. Zhang, Y.S., et al., Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos. Int. : J. Established as Result of Cooperation Between the European Foundation for Osteoporosis and the Nationa l Osteoporosis Foundation of the USA. 29(12): p. 2639-2644..10.1007/s00198-018-4649-8 ↗
37. Zhang, Y., et al., Exendin-4 gene modification and microscaffold encapsulation promote se lf-persistence and antidiabetic activity of MSCs. Sci. Adv.. 7(27): p. eabi4379..10.1126/sciadv.abi4379 ↗
38. Folkesson, E., et al., Differential protein expression in human knee articular cartilage and medial meniscus using two different proteomic methods: a pilot analysi s. BMC Muscoskel. Disord.. 19(1): p. 416..10.1186/s12891-018-2346-6 ↗
39. Pigeot, S., et al., Manufacturing of human tissues as off-the-Shelf grafts programmed to I nduce regeneration. Advanced materials (Deerfield Beach, Fla.). 33(43): p. e2103737..10.1002/adma.202103737 ↗
40. Gadjanski, I., K. Spiller, and G. Vunjak-Novakovic, Time-dependent processes in stem cell-based tissue engineering of arti cular cartilage. Stem cell Reviews Rep.. 8(3): p. 863-881..10.1007/s12015-011-9328-5 ↗
41. Dessau, W., et al., Changes in the patterns of collagens and fibronectin during limb-bud c hondrogenesis. J. Embryol. Exp. Morphol.. 57: p. 51-60..10.1242/dev.57.1.51 ↗
42. Scotti, C., et al., Engineering of a functional bone organ through endochondral ossificati on. Proc. Natl. Acad. Sci. USA. 110(10): p. 3997-4002..10.1073/pnas.1220108110 ↗
43. Osinga, R., et al., Generation of a bone organ by human adipose-derived stromal cells thro ugh endochondral ossification. Stem Cells Transl. Med.. 5(8): p. 1090-1097..10.5966/sctm.2015-0256 ↗
44. Guerrero, J., et al., Fractionated human adipose tissue as a native biomaterial for the gene ration of a bone organ by endochondral ossification. Acta Biomater.. 77: p. 142-154..10.1016/j.actbio.2018.07.004 ↗
45. Morimoto, Y., et al., TPT1 supports proliferation of neural stem/progenitor cells and brain tumor initiating cells regulated by macrophage migration inhibitory fa ctor (MIF). Neurochem. Res.. 47(9): p. 2741-2756..10.1007/s11064-022-03629-6 ↗
46. Aghajanian, P. and S. Mohan, The art of building bone: emerging role of chondrocyte-to-osteoblast t ransdifferentiation in endochondral ossification. Bone Res.. 6: p. 19..10.1038/s41413-018-0021-z ↗
47. Clowes, J.A., S. Khosla, and R. Eastell, Potential role of pancreatic and enteric hormones in regulating bone t urnover. J. Bone Miner. Res. : Off. J. Am. Soc. Bone Mineral Res.. 20(9): p. 1497-1506..10.1359/JBMR.050524 ↗
48. Jensen, N.W., et al., Associations between postprandial gut hormones and markers of bone rem odeling. Nutrients. 13(9): p. 3197..10.3390/nu13093197 ↗
49. Iepsen, E.W., et al., GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J. Clin. Endocrinol. Metabol.. 100(8): p. 2909-2917..10.1210/jc.2015-1176 ↗
50. Bergmann, N.C., et al., Separate and combined effects of GIP and GLP-1 infusions on bone metab olism in overweight men without diabetes. J. Clin. Endocrinol. Metabol.. 104(7): p. 2953-2960..10.1210/jc.2019-00008 ↗
51. Pazarci, Ö., et al., Evaluation of serum glucagon-like peptide 1 and vitamin D levels in el derly patients with bone fractures. Med. Princ. Pract. : Int. J. Kuwait Univ., Health Sci. Centre. 29(3): p. 219-224..10.1159/000502132 ↗
52. Nuche-Berenguer, B., et al., Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 di abetic states. Regul. Pept.. 159(1–3): p. 61-66..10.1016/j.regpep.2009.06.010 ↗
53. Zeng, Z., et al., MiR-27a-3p targets GLP1R to regulate differentiation, autophagy, and R elease of inflammatory factors in pre-osteoblasts via the AMPK signaling pathway. Front. Genet.. 12: p. 783352..10.3389/fgene.2021.783352 ↗
54. Pacheco-Pantoja, E.L., et al., Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol.. 11: p. 12..10.1186/1472-6793-11-12 ↗
55. Li, Z., et al., Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses os teoclastogenesis through the inhibition of NF-κB and MAPK pathways via GLP-1R. Biomed. & Pharmacother. = Biomed. & Pharmacother.. 130: p. 110523..10.1016/j.biopha.2020.110523 ↗
56. Zhang, L., et al., Relationship between glucagon-like peptide-1 receptor gene polymorphis m and bone mineral density in postmenopausal women in Shanghai. Ann. Palliat. Med.. 9(4): p. 1732-1741..10.21037/apm-19-396 ↗
57. Kitaura, H., et al., Effects of incretin-related diabetes drugs on bone formation and bone resorption. Int. J. Mol. Sci.. 22(12): p. 6578..10.3390/ijms22126578 ↗
58. Raufman, J.P., et al., Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from Guinea pig pancreas. Identification of a mammalia n analogue of the reptilian peptide exendin-4. J. Biol. Chem.. 267(30): p. 21432-21437..10.1016/S0021-9258(19)36628-1 ↗
59. Eng, J., et al., Isolation and characterization of exendin-4, an exendin-3 analogue, fr om Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas. J. Biol. Chem.. 267(11): p. 7402-7405..10.1016/S0021-9258(18)42531-8 ↗
60. Nauck, M.A., et al., GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of -the-art. Mol. Metabol.. 46: p. 101102..10.1016/j.molmet.2020.101102 ↗
61. De Spiegelaere, W., et al., Detection of hypoxia inducible factors and angiogenic growth factors d uring foetal endochondral and intramembranous ossification. Anat. Histol. Embryol. 39(4): p. 376-384..10.1111/j.1439-0264.2010.01005.x ↗
62. Kovacevic, A., et al., Expression of serum amyloid A transcripts in human bone tissues, diffe rentiated osteoblast-like stem cells and human osteosarcoma cell lines. J. Cell. Biochem.. 103(3): p. 994-1004..10.1002/jcb.21472 ↗
63. Lu, J.F., et al., Camptothecin effectively treats obesity in mice through GDF15 inductio n. PLoS Biol.. 20(2): p. e3001517..10.1371/journal.pbio.3001517 ↗
64. Mazor, R., et al., Matrix metalloproteinase-1-mediated up-regulation of vascular endothel ial growth factor-2 in endothelial cells. J. Biol. Chem.. 288(1): p. 598-607..10.1074/jbc.M112.417451 ↗
65. Bertrand-Philippe, M., et al., Regulation of tissue inhibitor of metalloproteinase 1 gene transcripti on by RUNX1 and RUNX2. J. Biol. Chem.. 279(23): p. 24530-24539..10.1074/jbc.M311804200 ↗
66. Saw, S., et al., Metalloprotease inhibitor TIMP proteins control FGF-2 bioavailability and regulate skeletal growth. J. Cell Biol.. 218(9): p. 3134-3152..10.1083/jcb.201906059 ↗
67. Salmi, A., et al., An integrative bioinformatics approach to decipher adipocyte-induced t ransdifferentiation of osteoblast. Genomics. 114(4): p. 110422..10.1016/j.ygeno.2022.110422 ↗
68. Li, J., et al., Exendin-4 regulates pancreatic ABCA1 transcription via CaMKK/CaMKIV pa thway. J. Cell Mol. Med.. 14(5): p. 1083-1087..
69. Xing, Z., et al., Endochondral ossification induced by cell transplantation of endotheli al Cells and bone marrow stromal cells with copolymer scaffold using a rat calvarial defect model. Polymers. 13(9): p. 1521..10.3390/polym13091521 ↗
70. Thompson, E.M., et al., An endochondral ossification-based approach to bone repair: chondrogen ically primed mesenchymal stem cell-laden scaffolds support greater Re pair of critical-sized cranial defects than osteogenically stimulated constructs in vivo. Tissue Eng. 22(5–6): p. 556-567..10.1089/ten.tea.2015.0457 ↗
71. Morimoto, S., et al., A Cartilaginous Construct With Bone Collar Exerts Bone-Regenerative Pr Operty via Rapid Endochondral Ossification. Stem Cell Reviews and Reports: p. 10.1007/s12015-023-10554-w..
72. Ayturk, U.M., et al., Single-cell RNA sequencing of calvarial and long-bone endocortical cel ls. J. Bone Miner. Res. : Off. J. Am. Soc. Bone Mineral Res.. 35(10): p. 1981-1991..10.1002/jbmr.4052 ↗
73. Jeyachandran, D., et al., A Bioglass-Poly(lactic-Co-Glycolic Acid) Scaffold@Fibrin Hydrogel Cons Truct to Support Endochondral Bone Formation. Advanced Healthcare Materials: p. e2300211..
74. Aprile, P. and D.J. Kelly, Hydrostatic pressure regulates the volume, aggregation and chondrogeni c differentiation of bone marrow derived stromal cells. Front. Bioeng. Biotechnol.. 8..10.3389/fbioe.2020.619914 ↗
75. Grogan, S.P., et al., Visual histological grading system for the evaluation of in Vitro–generated neocartilage. Tissue Eng.. 12(8): p. 2141-2149..10.1089/ten.2006.12.2141 ↗